ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

First, select a broad health condition.
33733 results sorted by trial registration date.
Clear all

  • Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

    This is a multi-centre, open label, interventional, comparative, phase I study to identify a safe and efficacious dose (within the range of 14.7mcg to 35.5 mcg) of PA5108 (PolyActiva product code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant in adults who have Primary Open Angle Glaucoma.

    Registration number:
    NCT04060758
    Broad health category:
    • Open Angle Glaucoma
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • NSW
    • SA
    • VIC
    • Not specified
    Gender:
    • All

  • Extravascular ICD Pivotal Study

    Pivotal Summary: The study is designed to demonstrate safety and efficacy of the Extravascular Implantable Cardioverter Defibrillator (EV ICD) System. Continued Access Summary: This study is designed to provide continued access to the Extravascular Implantable Cardioverter Defibrillator (EV ICD) System.

    Registration number:
    NCT04060680
    Broad health category:
    • Tachycardia
    • Ventricular Arrythmia
    Specific health category:
    • Not specified
    Trial focus:
    • Other
    Recruitment status:
    • Completed
    Recruitment sites:
    • NSW
    • SA
    • VIC
    • Not specified
    Gender:
    • All

  • Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

    The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.

    Registration number:
    NCT04060199
    Broad health category:
    • Duchenne Muscular Dystrophy
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

    Primary Objective: To determine whether amcenestrant per overall survival (os) improves progression free survival (PFS) when compared with an endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer Secondary Objectives: * To compare the overall survival in the 2 treatment arms * To assess the objective response rate in the 2 treatment arms * To evaluate the disease control rate in the 2 treatment arms * To evaluate the clinical benefit rate in the 2 treatment arms * To evaluate the duration of response in the 2 treatment arms * To evaluate the PFS according to the estrogen receptor 1 gene (ESR1) mutation status in the 2 treatment arms * To evaluate the pharmacokinetics of amcenestrant as single agent * To evaluate health-related quality of life in the 2 treatment arms * To compare the overall safety profile in the 2 treatment arms

    Registration number:
    NCT04059484
    Broad health category:
    • Breast Cancer Metastatic
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Stopped early
    Recruitment sites:
    • QLD
    • WA
    • Not specified
    Gender:
    • All

  • Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

    The purpose was to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of sapablursen administered subcutaneously to participants with non-transfusion dependent ß-Thalassemia Intermedia.

    Registration number:
    NCT04059406
    Broad health category:
    • Beta Thalassemia Intermedia
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Stopped early
    Recruitment sites:
    • NSW
    • VIC
    • WA
    • Not specified
    Gender:
    • All

  • Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

    This study evaluated the long-term safety, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes).

    Registration number:
    NCT04058366
    Broad health category:
    • Cystic Fibrosis
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

    This study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a gating or residual function mutation (F/G and F/RF genotypes).

    Registration number:
    NCT04058353
    Broad health category:
    • Cystic Fibrosis
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

    The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE have ongoing disease activity despite treatment with standard of care therapies.

    Registration number:
    NCT04058028
    Broad health category:
    • Systemic Lupus Erythematosus (SLE)
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • NSW
    • SA
    • Not specified
    Gender:
    • All

  • Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

    The purpose of this study is to evaluate the effect of JNJ-53718678 on the development of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTIs) in adult hematopoietic stem cell transplant (HSCT) recipients with RSV upper RTI.

    Registration number:
    NCT04056611
    Broad health category:
    • Respiratory Syncytial Virus Infections
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Stopped early
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects

    The study is designed to investigate the safety and tolerability of KBL697 in healthy volunteers. KBL697 has been developed as a potential new treatment for atopic dermatitis (AD).

    Registration number:
    NCT04056130
    Broad health category:
    • Atopic Dermatitis (AD)
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • VIC
    • Not specified
    Gender:
    • All
Tags:
  • Finding clinical trials